Sirius Therapeutics, Inc.
PrivateLast Round
Series B
Extension
May 9, 2025
Est. Valuation
$253M
Total Funding Raised
$147.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Sirius Therapeutics, Inc. operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B Extension round in May 2025.
Sirius Therapeutics, Inc. is a biotechnology company developing innovative siRNA therapies for global markets, focusing on cardiovascular and chronic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sirius Therapeutics, Inc. Comparables
Compare Sirius Therapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ADARx Pharmaceuticals | 86% | |
| Argo Biopharma | 84% | |
| Rona Therapeutics | 83% |
For institutional investors. Book with your work email.
Sirius Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | May 9, 2025 | ||||
| Series B | Oct 9, 2023 | ||||
| Series A | Jul 13, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sirius Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series B Extension |
| Creacion Ventures | Series B Extension, Series B, Series A |
| OrbiMed | Series B Extension, Series B, Series A |
| Hankang Capital | Series B Extension, Series B |
| Delos Capital Partners | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors increased 108% MoM, reaching 6.3K.
- May 27, 2026
Grew 29% QoQ, from 14 to 18 employees.
For institutional investors. Book with your work email.
Sirius Therapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sirius Therapeutics, Inc.'s valuation, stock price, and market status.
Is Sirius Therapeutics, Inc. a public or private company?
Sirius Therapeutics, Inc. is a private company.
What is the current stock price of Sirius Therapeutics, Inc.?
Sirius Therapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Sirius Therapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sirius Therapeutics, Inc. worth (valuation)?
Sirius Therapeutics, Inc.'s valuation is estimated at $253.0M based on funding round data.
Can I buy Sirius Therapeutics, Inc. stock?
Sirius Therapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sirius Therapeutics, Inc.'s last funding round?
Sirius Therapeutics, Inc.'s most recent funding round was Series B Extension on May 9, 2025.
Who are the main investors in Sirius Therapeutics, Inc.?
Key investors in Sirius Therapeutics, Inc. include Creacion Ventures, OrbiMed, Hankang Capital.
Will Sirius Therapeutics, Inc. IPO soon?
No public IPO plans have been announced for Sirius Therapeutics, Inc..
How can I track Sirius Therapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Sirius Therapeutics, Inc.'s shares on secondary markets.